Celgene (CELG -4.3%) gets FDA approval for its supplemental new drug application for Revlimid to...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene (CELG -4.3%) gets FDA approval for its supplemental new drug application for Revlimid to treat mantle cell lymphoma. The drug is already cleared for multiple myeloma, another white blood cell cancer. Analysts estimate the drug could generate around $5.9B in sales in 2016.